Introduction
============

Currently, the best-known treatment for severe lumbar stenosis refractory to non-operative treatment is decompressive laminectomy with or without fusion. It is important for the surgeon to convey the possible and likely suboptimal outcomes to the patient during the informed consent process. Common complications of decompressive laminectomies include a prolonged inpatient stay, dural tear, wound infection, urinary tract infection, pneumonia, perioperative hematoma, deep vein thrombosis, and pulmonary embolus \[[@b1-asj-2018-12-6-1043]\]. Additional risk factors include injuries to the nerves and the surrounding structures, incomplete resolution of preoperative symptoms, and postoperative pain.

An important distinction should be made between persistent preoperative symptoms and the evolution of a different pathology when addressing post laminectomy pain. In our experience, several patients who were seen for postoperative follow-up describe a new onset radicular pain that is different in character and nature from their preoperative pain. We termed this 'post-decompressive neuropathy' (PDN) because it is critical to understand the treatment modalities required for the optimal management of this constellation of symptoms and to assess the long-term prognostic significance of PDN for patients.

We defined and characterized the incidence, location, severity, duration, and patient/surgical risk factors associated with PDN with a prospectively administered, postoperative pain survey. This survey was designed to assess the unique characteristics and physiology of this pain syndrome. We used the Visual Analog Scale (VAS) as a portion of the survey as a means of providing objective, quantifiable date that lent itself to temporal analysis.

Materials and Methods
=====================

The study was approved by the Institutional Review Board at the University of Pittsburgh Medical Center (IRB approval no., PRO12090400) of University of Pittsburgh Medical Center; patients who consented to undergo a lumbar laminectomy with or without instrumented fusion for degenerative lumbar spine disease were prospectively followed up from July 2013 to December 2014. Patients with principal or secondary diagnoses of infection, trauma, or malignancy were excluded. Each surgery was performed by one of three fellowship trained spine surgeons at the same academic institution. All patients were consulted at their first postoperative visit. Patients for whom only one postoperative survey was completed were excluded (46 patients) ([Table 1](#t1-asj-2018-12-6-1043){ref-type="table"}).

Patients completed the postoperative questionnaires 3 weeks, 3 months, 6 months, and 1 year postoperatively. All surveys were completed independently by each patient. The questions were designed to characterize postoperative pain (Appendix 1). Patients were able to provide subjective and objective assessments of pain. The VAS was used to establish pain burden and to monitor pain progression. Careful attention was paid to the constellation of symptoms that characterized the temporal evolution of 'new' neuropathic pain, defined as a distributional pain complaint that was not observed or recorded preoperatively and was not the indication for the decompressive procedure. PDN was diagnosed when the patient exhibited the following four characteristics: (1) lower extremity pain different from the preoperative complaint (question 3), (2) leg pain that was worse than back pain (question 2), (3) a non-dermatomal pain pattern (question 4), and (4) nocturnal pain that often disrupted sleep (question 5). Patients were offered a chance to comment on the progress of their pain management at subsequent appointments.

A retrospective medical record review was performed for all the patients who fulfilled the study inclusion criteria to correlate their demographic characteristics, comorbidities, surgical factors, and perioperative complications with the occurrence of PDN.

The primary outcome measures included time until resolution, modalities considered effective in PDN treatment, modalities associated with unresolved PDN, nature and character of leg pain, as well as the progression of the VAS score over time.

Statistical analyses were performed by the authors using Prism ver. 7.0 (GraphPad, La Jolla, CA, USA). Fisher's exact test was used to compare the categorical variables. Patients with both early and late-onset PDN were compared to those who remained asymptomatic. We compared those patients with early and late pathological development. In all cases, *p*\<0.05 was considered statistically significant.

Results
=======

Of the 164 eligible patients who had completed at least one follow-up survey, 118 (72%) completed more than one survey. The average length of follow-up in this group was 196±112 days. Seventy-five patients (46%) reported symptoms characteristic of PDN in their initial questionnaire administered at 3 weeks postoperatively. The onset of symptoms within 30 days postoperatively was considered to indicate early-onset PDN. The early-onset PDN group included 40 women with a mean age of 57.4±11.7 years. Forty patients were obese (body mass index \[BMI\] \>30 kg/m^2^), and nine of these patients were classified as morbidly obese (BMI \>40 kg/m^2^). Fourteen patients had coexisting type II diabetes. Forty-eight patients underwent instrumented fusion, and 20 underwent revision procedures. Sixteen patients reported symptoms characteristic of PDN at 30 days postoperatively, defined here as lateonset PDN. Of these patients, seven were women and had a mean age of 60.5±11.2 years. Ten patients were obese (one with BMI \>40 kg/m^2^), and four had type II diabetes. Twelve patients underwent instrumented fusions, and four underwent revision surgeries ([Table 2](#t2-asj-2018-12-6-1043){ref-type="table"}).

The proportion of women who developed PDN was significantly higher than those who did not (52% versus 26%, *p*=0.03) ([Table 3](#t3-asj-2018-12-6-1043){ref-type="table"}). There were no statistically significant differences in the age, BMI, incidence of diabetes, mean number of laminectomy or fusion levels, use of instrumentation, use of bone morphogenic protein (BMP), or the incidence of intraoperative dural tears in the patients with and without PDN. There was no significant difference between the number of levels included in the fusion or whether the surgery was a revision procedure amongst asymptomatic patients or patients who developed early- or late-onset PDN ([Table 2](#t2-asj-2018-12-6-1043){ref-type="table"}). Revision procedures did not predispose a patient to PDN. Compared to late PDN, early PDN was more likely to be categorized as a dull ache; however, this difference was not significant (60% versus 31%, *p*=0.052) ([Table 4](#t4-asj-2018-12-6-1043){ref-type="table"}). There was no significant difference in the characterization of leg pain between early- and late-onset PDN patients ([Table 5](#t5-asj-2018-12-6-1043){ref-type="table"}).

Time until PDN symptom resolution ranged from within 1 month to 1 year. Patients were considered to have persistent PDN if their symptoms persisted for more than 1 year postoperatively. Complete resolution of symptoms was reported by 81% of those with early PDN and 63% of those with late PDN at 1 year postoperatively (*p*=0.11). Total 20 patients, 14 of 75 (19%) with early PDN and 6 of 16 (38%) with late PDN never experienced complete symptom resolution as per the patient-reported survey responses. Early PDN resolved within 1 month in 22 out of 75 patients (29%), improved within 3 months in 47 (63%), resolved within 6 months in 56 (75%), and alleviated within 1 year postoperatively in 61 of the patients (81%) ([Fig. 1](#f1-asj-2018-12-6-1043){ref-type="fig"}). There was no statistically significant difference between the rate of symptom resolution or time to symptom resolution between early and late PDN groups ([Table 6](#t6-asj-2018-12-6-1043){ref-type="table"}). Opioids were more effective in patients with early onset PDN than in those with late onset PDN (85% versus 44%, *p*=0.001) ([Table 7](#t7-asj-2018-12-6-1043){ref-type="table"}). Gabapentin was most commonly cited as an attempted treatment method among patients with PDN whose symptoms did not resolve (70% versus 31%, *p* =0.003) ([Table 8](#t8-asj-2018-12-6-1043){ref-type="table"}).

1. Case example
---------------

A 56-year-old man with a previous history of a prior microdiscectomy at L4--5 (motor strength graded at 4/5). Magnetic resonance imaging (MRI) demonstrated congenital spinal stenosis from L2--5, with a recurrent herniated disc at L4--5. The patient's radiographic imaging was consistent with L4--5 spondylolisthesis. After failing nonoperative management, the patient underwent a L2--5 revision laminectomy with a L4--5 posterolateral instrumented fusion. The surgical and immediate postoperative course was uneventful, and the patient was discharged on postoperative day 3.

Two weeks postoperatively, the patient followed up in clinic and endorsed severe bilateral leg pain that was different in nature from his preoperative unilateral (left) leg pain. His preoperative L5 radiculopathy and foot drop had improved significantly; however, the patient now endorsed non-dermatomal pain and paresthesias in both legs. The symptoms worsened at night and were strong enough to wake him from sleep; they were only partially relieved by ambulation. He did not report any fevers, chills, or other constitutional symptoms. His symptoms were purely sensory, with no motor involvement.

An MRI with gadolinium contrast revealed an enhancing cauda equina, indicative of significant endoneural edema and a leaky blood brain barrier ([Fig. 2](#f2-asj-2018-12-6-1043){ref-type="fig"}). The patient lacked clinical manifestations that suggested common postoperative complications or a separate disease process, such as spinal meningitis, Guillain-Barre Syndrome, and chronic inflammatory polyneuropathy. As the aforementioned conditions were essentially ruled out, which helped to support the alternative diagnosis of PDN. The patient returned to clinic for continued monitoring and reassurance. He was medically managed with a short course of steroids (1 week) and high dose gabapentin (1,200 mg, twice daily) for 3 months, during which time the patient noted reduction and eventual relief from pain. Gabapentin was gradually weaned down over 5 months; by this time, the patient's symptoms had resolved.

Discussion
==========

The primary aim of this study was to name and characterize a common constellation of clinical symptoms after lumbar laminectomy with or without instrumented fusion. Our data suggest that a considerable proportion (77%) of our patients developed severe neuropathic pain that differed from their preoperative indication. Optimal management was limited by an elusive diagnosis. PDN diagnosis was established following careful assessment of patient-reported symptoms and the results of prospective survey analysis (including the VAS). A combination of the targeted questionnaire and validated outcome score was used to highlight the risk factors for and natural history of the pathology. Diagnosis of PDN was only conferred after careful exclusion of more commonly occurring postoperative pathologies.

The initial mention of 'new' postoperative pain ranged from several days to weeks after surgery with bimodal distribution, presenting early (within 30 days postprocedure) or late (more than 30 days post-procedure). In our experience, PDN can be debilitating for the patients because the symptoms may last from several weeks to months. Despite being a commonly occurring condition, the postoperative pain phenomenon has evaded precise characterization and protocol for optimal management.

PDN is characterized by the delayed onset (usually several days to weeks) of new lower extremity neuropathic pain or paresthesia in a non-dermatomal distribution following a lumbar laminectomy and/or fusion procedure. PDN pain commonly worsens at nighttime (significant enough to wake patients from sleep). PDN is not exacerbated by postural changes and is often partially relieved by walking. Symptoms are purely sensory without dermatomal distribution. There is no motor involvement. The symptoms characters remained constant throughout the follow-up period; thus, the phenomenon was further distinguished by the lack of symptom progression.

Several prior reports note a post-laminectomy pain syndrome; however, without significant sample size or organization to propose an independent diagnosis, PDN may be distinguished from 'post laminectomy syndrome (PLS),' or 'failed back surgery syndrome (FBSS),' a catastrophic complication of lumbar laminectomy. PLS or FBSS is defined as "lumbar spinal pain of unknown origin either persisting despite surgical intervention or appearing after surgical intervention for spinal pain originally in the same topographical location \[[@b2-asj-2018-12-6-1043],[@b3-asj-2018-12-6-1043]\]." Unlike PLS, PDN symptoms differ from the preoperative issues and often resolve within 3--6 months with only supportive care. Further, PDN is purely a lower extremity phenomenon. Therefore, the presence of back pain may be more indicative of PLS.

Rowan et al. \[[@b4-asj-2018-12-6-1043]\] demonstrated an association between BMP use during spinal fusions with posteriorly inserted interbody cages and the incidence of postoperative radiculitis. The authors proposed that the mechanism for this new pain was an excessive inflammatory response and ectopic bone formation \[[@b5-asj-2018-12-6-1043]-[@b9-asj-2018-12-6-1043]\]. In a cohort-controlled study, Lykissas et al. \[[@b10-asj-2018-12-6-1043]\] found a significantly higher rate of persistent postoperative neurologic (motor and sensory) deficit and pain in patients who had received rh-BMP-2. However, in contrast to this BMP-associated radiculitis, PDN is most severe at nighttime, is purely sensory, and has non-dermatomal in distribution. Our results further suggest that PDN is not associated with BMP use.

Significantly more female patients reported PDN symptoms. Ineffective pain control in women has been recognized as a factor for the different postoperative outcomes across sexes \[[@b11-asj-2018-12-6-1043]\]. Shabat et al. \[[@b12-asj-2018-12-6-1043]\] postulated that sex-related differences in the patient-reported outcome following lumbar spine decompression might be attributable to the difference in the hormone levels of the sexes that predispose them to differences in the pain perception despite similar prescribed pain control regimens. Female patients are known to experience less pain relief and were less satisfied with the postoperative results \[[@b12-asj-2018-12-6-1043]\]. In a benchtop study, Cicero et al noted sex-based differences in the pain response despite the opioid dose being doubled in women. The authors concluded that the sex differences in pain response were likely secondary to inherent differences in brain sensitivity rather than pharmacokinetics \[[@b11-asj-2018-12-6-1043],[@b13-asj-2018-12-6-1043]\]. Women undergo lumbar laminectomies at later stages of the disease; therefore likely imparting a lower preoperative functional status that negatively affects postoperative recovery \[[@b14-asj-2018-12-6-1043]\].

The pathophysiology of PDN is unclear. Imaging results obtained in the workup of the cited case example showed enhancement of the cauda equine on contrast-MRI. It is possible that surgical trauma to the cauda equina or dorsal root ganglion initiated an inflammatory cascade similar to a demyelinating process. Hugon et al. \[[@b15-asj-2018-12-6-1043]\] hypothesized that excitatory neurotransmitters exert neurotoxic effects on the peripheral nerves, leading to endoneural edema and demyelination. L-glutamate and L-aspartate cause excitation by binding to the N-methyl-D-aspartate receptor and likely cause toxic effects (demyelination and resultant neuropathy) through this mechanism. We hypothesize that endoneural damage with partial demyelination may be the underlying pathophysiology of PDN. However, without a large body of correlative imaging, this theory needs further validation. Reduction in the PDN symptoms may correspond with the resolution of this demyelinating process. Symptoms may be attributable to the classic localized 'epineural edema and nerve strangulation,' considering the absence of symptom progression associated with nerve compression that typically manifests with both sensory and motor components \[[@b16-asj-2018-12-6-1043],[@b17-asj-2018-12-6-1043]\].

The limitations of our study include the inherent subjectivity of patient-reported outcomes. Neuropathy was used as a generic term to describe a neurogenic, distributional symptom. However, histological examination was not possible for these patients because we observed a postoperative phenomenon. However, future work may consider additional nerve studies, such as magnetic resonance neurography, that would enable the objective characterization of the symptoms. As is the case with several other pain related syndromes, there may be psychogenic causes associated with the development and characterization of the symptoms. We did not consider the primary diagnoses of mental health disorders or the duration of preoperative symptoms in our analysis. We isolated the symptoms most unique to the specific set of factors that appeared to indicate PDN. Our analysis is also limited by the lack of an accepted outcome measure designed to identify the patients with PDN. Although our questionnaire was designed to capture PDN, it has not been previously validated in studies with a large sample size. The questionnaire was designed to highlight the differences between usual postoperative pain complaints and this postoperative pain phenomenon that has not yet been described. These patients were selected because of pain complaints that appeared to be radicular in nature. We believe that it is more likely that these patients' complaints are neuropathic because they were remote from the surgical site and were distributional. However, the accuracy of our data may have been affected by the subjectivity of this complaint; therefore, a larger sample size is needed to validate our incidence rate. Pain level was assessed at different intervals throughout the study. The VAS was used to assess pain given that it is an objective and validated outcome measure. While we analyzed a large sample size during the study period, our findings suggest that this work is insufficient to fully characterize PDN. Future work will continue using the same metric to capture a larger sample of patients and focus on capturing mid- and long-term outcomes of patients previously treated for PDN.

Conclusions
===========

This study presents the initial characterization of PDN, a largely self-limiting condition that occurred in approximately 77% of the patients who underwent a lumbar laminectomy with or without instrumented fusion at our institution. Female sex was associated with PDN development, and the use of opioids was most strongly associated with symptom resolution among those with early-onset PDN (symptom reliefs within 30 days postoperatively). Further prospective studies involving a larger sample size are warranted to fully characterize PDN and describe effective treatment modalities for this condition.
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###### 

Cohort characteristics (n=118)

  Characteristic                        Value
  ------------------------------------- -----------
  Patient demographics                  
   Males                                64 (54)
   Age (yr)                             58.0±11.9
   BMI (kg/m^2^)                        31.2±5.6
    Obese (BMI \>30 kg/m^2^)            64 (54)
    Morbidly obese (BMI \>40 kg/m^2^)   10 (8.4)
   Diabetes                             22 (18.6)
  Surgical intervention                 
   \# Laminectomy levels                3.6±1.2
   \# Fusion levels                     1.5±1.8
   Instrumentation                      75 (63)
   Revision procedure                   32 (27)
   Use of morphogenic protein           4 (3.4)
  Complications                         
   Dural tear                           18 (15.2)
   Pulmonary embolus                    1 (0.8)
   Infection                            0

Values are presented as number (%) or mean±standard deviation.

BMI, body mass index.

###### 

Group demographics and surgical characteristics for early versus late PDN

  Characteristic                            No pain (n=27)   Early PDN (n=75)   Late PDN (n=16)   *p*-value
  ----------------------------------------- ---------------- ------------------ ----------------- -----------
  Age (yr)                                  56.5±12.3        57.4±11.7          60.5±11.2         0.55
  Sex (male:female)                         20:7             35:40              10:7              0.06
  BMI (kg/m^2^)                             30.1±3.6         31.5±6.4           31.7±4.6          0.49
  Obese (BMI \>30 kg/m^2^)                  14               40                 10                0.53
  Morbidly obese (BMI \>40 kg/m^2^)         0                9                  1                 0.40
  \# Laminectomy levels                     3.3±1.1          3.6±1.2            3.7±1.6           0.53
  \# Fusion levels                          1.6±2.2          1.4±1.7            1.4±1.7           0.94
  Instrumentation                           15               48                 12                0.32
  Revision procedure                        8                20                 4                 0.97
  Diabetic                                  4                14                 4                 0.80
  Dural tear                                3                13                 2                 0.71
  Bone morphogenic protein used in fusion   1                3                  0                 0.71
  Pulmonary embolus                         0                1                  0                 0.32

Values are presented as mean±standard deviation or number.

PDN, post-decompressive neuropathy; BMI, body mass index.

###### 

Patient demographics and surgical characteristics of developing PDN

  Characteristic                       No PDN (n=27)   PDN (n=91)   *p*-value
  ------------------------------------ --------------- ------------ -----------------------------------------------------------
  Age (yr)                             56.6±12.3       57.9±11.6    0.59
  Sex (male:female)                    20:7            44:47        0.03^[\*](#tfn1-asj-2018-12-6-1043){ref-type="table-fn"}^
  BMI (kg/m^2^)                        30.1±3.6        31.6±6.1     0.24
  Obese (BMI \>30 kg/m^2^)             14              50           0.83
  Morbidly obese (BMI \>40 kg/m^2^)    0               10           0.11
  \# Laminectomy levels                3.3±1.1         3.6±1.3      0.26
  \# Fusion levels                     1.6±2.2         1.4±1.7      0.75
  Instrumentation                      15              60           0.37
  Revision procedure                   8               24           0.81
  Diabetic                             4               18           0.78
  Dural tear                           3               15           0.76
  Morphogenic protein used in fusion   1               3            \>0.99

Values are presented as mean±standard deviation or number.

PDN, post-decompressive neuropathy; BMI, body mass index.

*p* \<0.05.

###### 

Nature of leg complaint

  Variable         Early PDN (n=75)   Late PDN (n=16)   *p*-value
  ---------------- ------------------ ----------------- -----------
  Intermittent     37                 10                0.41
  Constant         27                 5                 0.78
  Burning          20                 6                 0.38
  Sharp/stabbing   27                 4                 0.56
  Dull ache        45 (60)            5 (31.3)          0.052

Values are presented as number or number (%).

PDN, post-decompressive neuropathy.

###### 

Character of leg pain

  Variable               Early PDN (n=75)   Late PDN (n=16)   *p*-value
  ---------------------- ------------------ ----------------- -----------
  Worse at night         24 (32)            6 (37.5)          0.77
  Wakes up from sleep    31 (41.3)          6 (37.5)          \>0.99
  Worsened by activity   20 (26.7)          7 (43.8)          0.23

Values are presented as number (%).

PDN, post-decompressive neuropathy.

###### 

Time to resolution of leg pain

  Variable         Early PDN (n=75)   Late PDN (n=16)   *p*-value
  ---------------- ------------------ ----------------- ----------------
  Within 1 mo      22                 \-                Not applicable
  Within 3 mo      47                 8                 0.40
  Within 6 mo      56                 10                0.36
  Within 1 yr      61                 10                0.11
  Never resolved   14 (18.7)          6 (37.5)          0.11

Values are presented as number or number (%).

PDN, post-decompressive neuropathy.

###### 

Pain control modalities most associated with resolution of symptoms as described by patients

  Variable                                Early PDN (n=75)   Late PDN (n=16)   *p*-value
  --------------------------------------- ------------------ ----------------- ------------------------------------------------------------
  Medrol dose pak                         12                 1                 0.45
  Physical therapy                        40                 11                0.28
  Neurontin                               29                 7                 0.78
  Opioids                                 64 (85.3)          7 (43.8)          0.001^[\*](#tfn2-asj-2018-12-6-1043){ref-type="table-fn"}^
  Non-steroidal anti-inflammatory drugs   38                 7                 0.78

Values are presented as number or number (%).

PDN, post-decompressive neuropathy.

*p* \<0.05.

###### 

Pain control modalities most associated with unresolved symptoms as described by patients

  Variable                                PDN resolved (n=71)   Unresolved PDN (n=20)   *p*-value
  --------------------------------------- --------------------- ----------------------- ------------------------------------------------------------
  Medrol dose pak                         8                     5                       0.15
  Physical therapy                        38                    13                      0.45
  Neurontin                               22 (31.0)             14 (70.0)               0.003^[\*](#tfn3-asj-2018-12-6-1043){ref-type="table-fn"}^
  Opioids                                 56                    18                      0.34
  Non-steroidal anti-inflammatory drugs   34                    11                      0.62

Values are presented as number or number (%).

PDN, post-decompressive neuropathy.

*p* \<0.05.
